Abstract | BACKGROUND: OBJECTIVE: To assess whether spironolactone treatment improves HS disease severity and patient-reported pain. METHODS: We performed a single-center chart review of female patients with HS who were treated with spironolactone between 2000 and 2017. Primary outcome measurements included the HS Physician's Global Assessment (HS- PGA), Hurley staging, inflammatory lesion count, fistula count, and a numeric rating scale for pain. RESULTS: On average, subjects were exposed to 75 mg of spironolactone daily over a 7.1-month follow-up period. Patients achieved significant disease improvement with regard to pain (Δ-1.5 [P = .01]), inflammatory lesions (Δ-1.3 [P = .02]), and HS- PGA score (Δ-0.6 [P < .001]). As expected, no change was found for Hurley stage (Δ0 [P = .32]) or fistulas (Δ0 [P = .73]). There was no difference in improvement between subjects who received less than 75 mg of spironolactone daily (n = 25; average dose, 45 mg/d) and those who received more than 100 mg daily (n = 21; average dose, 112 mg/d). LIMITATIONS: Retrospective nature, limited sample size, and variations in severity measures documented were limiting factors. CONCLUSIONS: Management of HS with spironolactone reduces lesion count, HS- PGA score, and pain. Lower doses appear to be effective and may be an appropriate option for patients with tolerability concerns.
|
Authors | Nicole M Golbari, Martina L Porter, Alexa B Kimball |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 80
Issue 1
Pg. 114-119
(Jan 2019)
ISSN: 1097-6787 [Electronic] United States |
PMID | 30003993
(Publication Type: Journal Article)
|
Copyright | Copyright © 2018 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Androgen Antagonists
- Spironolactone
|
Topics |
- Adult
- Androgen Antagonists
(therapeutic use)
- Female
- Hidradenitis Suppurativa
(drug therapy)
- Humans
- Retrospective Studies
- Spironolactone
(therapeutic use)
- Young Adult
|